Synageva BioPharma Names New Board Member
Synageva BioPharma has appointed Mark Goldberg, senior vice president of clinical research at Genzyme and a medical oncologist and hematologist, to the company’s board of directors.
Dr Goldberg first joined Genzyme in 1996 as medical director for oncology and following several promotions, has held his current position of senior vice president of clinical research since 2000.
Prior to working at Genzyme, Dr Goldberg was a full-time staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments.
Sanj Patel, president and CEO of Synageva, said: “Having worked very closely with Dr Goldberg for almost 10 years at Genzyme, I am confident Mark will provide critical insight into the execution of our clinical development and product commercialization strategies. Our proprietary protein expression system is enabling us to generate a diverse pipeline of follow-on, next-generation and novel monoclonal antibodies, cytokines and other biopharmaceuticals.
“These products are intended for use in a variety of therapeutic areas such as oncology, autoimmune and metabolic disorders. Mark’s extensive clinical development experience in these areas and others will be instrumental as Synageva provides alternative and improved products for patients around the world.”